Cancer, Malnutrition (Calorie)
Conditions
Brief summary
The goal of this clinical trial is to demonstrate safety and efficacy of Supportan® Drink (three flavors:Tropical Fruits, Cappuccino, and Pineapple-Coconut), administered as oral nutritional supplement, that will be taken in addition to the patient's normal dietary intake to meet the daily nutritional targets. in cancer patients. The main questions it aims to answer are: Primary Efficacy Endpoint 1. Change in body weight from Baseline to end of treatment at Week 4 (Week 4 -Baseline) Secondary Efficacy Endpoints 1\. Change in CRP from Baseline to Week 2 and to end of treatment at Week 4 (Week 2 - Baseline, Week 4 -Baseline) Participants will be enrolled in one of three flavor group by his/her recruiting time. Each subject needs visit hospital at baseline, week 2 and week 4 for checkups and test. And he/she needs take two bottles of Supportan Drink per day. During the study periods, subjects need write down his/her dietary records every day for evaluation.
Interventions
DIETARY_SUPPLEMENTSupportan® Drink, flavour Tropical Fruits
flavour Tropical Fruits
DIETARY_SUPPLEMENTSupportan® Drink, flavour Cappuccino
flavour Cappuccino
DIETARY_SUPPLEMENTSupportan® Drink, flavour Pineapple-Coconut
flavour Pineapple-Coconut
Sponsors
Fresenius Kabi Taiwan Ltd.
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Patients receiving chemotherapy and/or radiotherapy, or immunotherapy, or targeted therapy; 2. Patient with diagnosed cancer of any type (e.g., head and neck cancer, lung cancer, digestive tract cancer, breast cancer); 3. Patient with or at risk of malnutrition defined as meeting Malnutrition Universal Screening Tool (MUST) with score ≥2; 4. Capable of using oral nutritional supplementation; 5. Written informed consent from patient.
Exclusion criteria
1. Patient with documented diagnosis of liver, kidney or heart disease in the hospital's electronic medical record (EMR); severity of disease evaluated by Investigator as not being suitable to participate in this study; 2. Current alcohol or substance abuse as assessed by Investigator; 3. Patient had a stroke in the past year and is after Investigator assessment judged as not yet clinically stable at the time of screening; 4. Patients who are diagnosed with mental illness or depression assessed by the Investigator as too severe for being suitable to participate in this study; 5. Pregnant or breastfeeding woman; 6. Allergic to any ingredient of the investigational products; 7. Patients receiving or having received standard (not disease specific) oral nutritional supplements (ONS), standard enteral formula/tube feeding or standard parenteral cancerspecific nutrition supplements in the last 3 days; 8. Patients receiving or having received ONS, enteral formula/tube feeding or parenteral nutrition with high fish oil or high EPA/DHA content (above 1 g/day) in the last 28 days; 9. Current use of medication, food supplements or ONS containing more than 500 mg of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA)/day or fish oil capsules/supplements containing more than 500 mg EPA and DHA/day at screening; 10. Transfusion of blood products within 1 week before screening; 11. Surgery scheduled during the trial; 12. Participation in other clinical trials using investigational drugs within 14 days before the start of the trial or during the trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in body weight from Baseline to end of treatment at Week 4 (Week 4 -Baseline) | 4 weeks |
Secondary
| Measure | Time frame |
|---|---|
| Change in CRP from Baseline to Week 2 and to end of treatment at Week 4 (Week 2 - Baseline, Week 4 - Baseline). | 4 weeks |
| Change in body weight from Baseline to Week 2 (Week 2 - Baseline). | 2 weeks |
| Change in BMI from Baseline to Week 2 and to end of treatment at Week 4 (Week 2 - Baseline, Week 4 - Baseline). | 4 weeks |
| Change in calorie intake from Baseline to Week 2 and to end of treatment at Week 4 (Week 2 - Baseline, Week 4 - Baseline) using 3-day Dietary Records and additional intake of calories and protein from Supportan® Drink. | 4 weeks |
| Investigational product (IP) treatment compliance rate (%) calculated from patient IP diaries. | 4 weeks |
| Change in protein intake from Baseline to Week 2 and to end of treatment at Week 4 (Week 2 - Baseline, Week 4 - Baseline) using 3-day Dietary Records and additional intake of calories and protein from Supportan® Drink. | 4 weeks |
Countries
Taiwan
Outcome results
None listed